Man aged ≥ 18 years

Histologically proven metastatic prostate adenocarcinoma,

Patient undergoing chemotherapy according to the following conventional scheme: 12 courses of Docetaxel every two weeks

Patient who signed their informed consent

Patient benefiting from social security coverage

Patient treated and followed in the center for the duration of the study (6 months maximum).

Minimum age: 18

Patient participating in another clinical trial on an experimental molecule

Patient who received previous chemotherapy

Patient unable to submit to protocol monitoring for psychological, social, family or geographic reasons

Patient deprived of their liberty or under guardianship

Patient with underlying or concomitant pathology incompatible with inclusion in the trial, whether psychiatric or somatic